ARTICLE | Company News
bluebird bio, Medigene deal
October 3, 2016 7:00 AM UTC
Medigene and bluebird partnered to develop and commercialize T cell receptor (TCR) immunotherapies against four undisclosed targets to treat cancer. Medigene will be responsible for the delivery of t...